Drug intelligence / Profile preview

MDPK67b

Development stage
Phase 1
Lead developer
Med Discovery
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous, Topical
01

Overview

MDPK67b is a recombinant protease inhibitor developed by Med Discovery SA for the treatment of prostate cancer. It is designed to target and inhibit human kallikrein-related peptidases (KLKs), specifically KLK2, KLK4, and KLK14. These serine proteases are downstream targets of the androgen receptor (AR) and play significant roles in prostate cancer progression and the transition to castration-resistant states. By inhibiting these secreted KLKs, MDPK67b aims to downregulate AR signaling, reduce cell proliferation, and induce apoptosis in tumor cells. The drug has been evaluated in Phase I clinical trials for safety and pharmacokinetics in healthy volunteers and in Phase Ib studies for preoperative treatment in patients with untreated prostate cancer.

Other names
KLK inhibitor MDPK67b
02

Targets

KLK4 (Kallikrein-related peptidase 4)HK2 (Hexokinase Type II)KLK14 (Kallikrein-related peptidase 14)

Beyond the preview

Go deeper on MDPK67b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDPK67b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call